Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.

about

Precision Therapy of Head and Neck Squamous Cell Carcinoma.

P2860

Q52591781-28E68A79-6DA8-4228-A403-DF0E06E33F7E

P2860

Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.

Item

http://www.wikidata.org/entity/Q54256927

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.

@en

Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.

@nl

type

Item

label

Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.

@en

Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.

@nl

prefLabel

Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.

@en

Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.

@nl

P1476

Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.

@en

P2093

D Sun

http://www.w3.org/2001/XMLSchema#string

K Sansanaphongpricha

http://www.w3.org/2001/XMLSchema#string

M E P Prince

http://www.w3.org/2001/XMLSchema#string

Y L Lei

http://www.w3.org/2001/XMLSchema#string

Y S Tan

http://www.w3.org/2001/XMLSchema#string

P2860

Immunotherapy for head and neck cancer: latest developments and clinical potential

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

Comprehensive genomic characterization of head and neck squamous cell carcinomas

Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome

The mutational landscape of head and neck squamous cell carcinoma

Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma

Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells.

The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells.

Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia.

P304

627-634

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0022034518764416

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

G T Wolf

P577

2018-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29533731

http://www.w3.org/2001/XMLSchema#string

P932

5960883

http://www.w3.org/2001/XMLSchema#string

Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.

about

P2860

P2860

Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932